DOI: 10.12890/2021_002352

Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes

Authors

  • Morten Hindsø Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark
  • Christoffer Martinussen Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark
  • Maria Saur Svane Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark
  • Simon Veedfald Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
  • Birthe Gade-Rasmussen Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark
  • Torben Hansen The Novo Nordisk Foundation Center for Basic Metabolic Research, Section for Metabolic Genetics, University of Copenhagen, Copenhagen, Denmark
  • Sten Madsbad Department of Endocrinology, Hvidovre Hospital, Hvidovre, Denmark

morten.hindsoe@regionh.dk

Keywords

Neonatal diabetes, KCNJ11, sulfonylurea, GLP-1

Abstract

Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient. For the first time, we present a case of successful use of a GLP-1 receptor agonist as add-on therapy in the treatment of a patient with KCNJ11 neonatal diabetes and insufficient effect of sulfonylurea monotherapy. Good glycaemic control was maintained with a HbA1c level of 48 mmol/mol (6.5%) at the end of 26 months’ follow-up.

View the entire article

Downloads

References

  1. Lemelman MB, Letourneau L, Greeley SAW. Neonatal diabetes mellitus: an update on diagnosis and management. Clin Perinatol 2018;45(1):41–59.
  2. Proks P, Antcliff JF, Lippiat J, Gloyn AL, Hattersley AT, Ashcroft FM. Molecular basis of Kir6.2 mutations associated with neonatal diabetes or neonatal diabetes plus neurological features. Proc Natl Acad Sci USA 2004;101(50):17539–17544.
  3. Bowman P, Sulen Å, Barbetti F, Beltrand J, Svalastoga P, Codner E, et al. Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. Lancet Diabetes Endocrinol 2018;6(8):637–646.
  4. Gade-Rasmussen B, Madsbad S, Svane MS, Martinussen C, Hansen T. [Successful treatment of KCNJ11 neonatal diabetes without insulin]. Ugeskr Laeger 2018;180(46):V08180547.
  5. Sastre J, Luque A, del Val F, Aragonés A, López J. Long-term efficacy of glibenclamide and sitagliptin therapy in adult patients with KCNJ11 permanent diabetes. Diabetes Care 2014;37(3):e55–56.

Published

2021-03-31

Issue

Vol. 8 No. 3 (2021)

How to Cite

1.
Hindsø M, Martinussen C, Svane MS, Veedfald S, Gade-Rasmussen B, Hansen T, et al. Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes. EJCRIM [Internet]. 2021 Mar. 31 [cited 2026 Nov. 3];8(3). Available from: https://ejcrim.com/index.php/ejcrim/article/view/2352